Researcher
An Coosemans
- Disciplines:Cancer therapy, Cancer biology, Neurosurgery
Affiliations
- Laboratory for Tumor Immunology and Immunotherapy (Division)
Responsible
From1 Oct 2019 → Today - Laboratory for Tumor Immunology and Immunotherapy (Division)
Member
From1 Sep 2016 → Today - Gynaecological Oncology (Division)
Member
From1 Oct 2013 → 31 Aug 2016 - Allergy and Clinical Immunology Research Group (Division)
Member
From1 Oct 2012 → 30 Sep 2013
Projects
1 - 10 of 18
- Development of tumor-derived dendritic cell therapies to prevent ovarian cancer metastasisFrom13 Nov 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- How to deal with recurrent ovarian cancer: a new approach.From1 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Developing combinatorial immunotherapy for glioblastomaFrom7 Nov 2022 → TodayFunding: Foundations, funds and other with scientific goal
- Next-generation, multi-technology immune-monitoring and easy-access spectral flow cytometryFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- DIPITO: valorisation of deep immune profiling and novel immunotherapeutics for oncology.From1 Oct 2021 → TodayFunding: IOF - mandates
- Preclinical evaluation of novel radionuclide therapies in different cancer modelsFrom8 Jul 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Deciphering the dendritic cell compartment in ovarian cancer to assess their potential as tumor vaccines.From1 Jan 2021 → TodayFunding: FWO research project (including WEAVE projects)
- Spectral flowcytometry (Cytek Aurora)From1 Jan 2021 → 31 Dec 2022Funding: BOF - scientific equipment program
- Deciphering the dendritic cell compartment in ovarian cancer to assess their potential as tumor vaccinesFrom8 Oct 2020 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Rational approach for immunotherapy in ovarian cancer.From1 Sep 2020 → TodayFunding: Foundations, funds and other with scientific goal
Publications
41 - 50 of 114
- Trial watch: dendritic cell vaccination for cancer immunotherapy(2019)
Authors: Jenny Sprooten, Jolien Ceusters, An Coosemans, Patrizia Agostinis, Steven De Vleeschouwer, Abhishek Garg
- Myeloid-derived suppressor cells at diagnosis may discriminate between benign and malignant ovarian tumors(2019)
Authors: An Coosemans, Thaïs Baert, Jolien Ceusters, Pieter Busschaert, Chiara Landolfo, Anne-Sophie Van Rompuy, Wouter Froyman, Patrick Neven, Ben Van Calster, Ignace Vergote, et al.
Pages: 1381 - 1388 - Increased Immunosuppression Is Related to Increased Amounts of Ascites and Inferior Prognosis in Ovarian Cancer(2019)
Authors: An Coosemans, Thaïs Baert, Roxanne Wouters, Jolien Ceusters, Annouschka Laenen, Vincent Vandecaveye, Ignace Vergote
Pages: 5953 - 5962 - Immune-driven therapeutic combinations in a new mouse model of high-grade glioma(2019)
Authors: Matteo Riva, An Coosemans, Marc Van Ranst
- CT-2A neurospheres-derived high-grade glioma in mice: a new model to address tumor stem cells and immunosuppression(2019)
Authors: Matteo Riva, Roxanne Wouters, Sarah Belderbos, David Nittner, Dietmar Thal, Thaïs Baert, Willy Gsell, Uwe Himmelreich, Marc Van Ranst, An Coosemans
- Circulating Protein Biomarkers to Differentiate Uterine Sarcomas from Leiomyomas(2019)
Authors: Thaïs Baert, Thierry Van den Bosch, An Coosemans
Pages: 3981 - 3989 - Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer(2019)
Authors: Thaïs Baert, Ann Vankerckhoven, Matteo Riva, Ignace Vergote, An Coosemans
- Combining conventional therapy with immunotherapy: A risky business?(2019)
Authors: An Coosemans, Ann Vankerckhoven, Thaïs Baert, Matteo Riva, Michel Delforge, Ignace Vergote
Pages: 41 - 44 - Combining conventional therapy with immunotherapy: A risky business?(2019)
Authors: An Coosemans, Ann Vankerckhoven, Thaïs Baert, Louis Boon, Hanne Ruts, Matteo Riva, Sarah Blagden, Michel Delforge, Nicole Concin, Mansoor Mirza, et al.
Pages: 41 - 44 - Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study(2019)
Authors: Wouter Froyman, Chiara Landolfo, Bavo Campo, Laure Wynants, An Coosemans, Ignace Vergote, Jan Verbakel, Tom Bourne, Ben Van Calster, Dirk Timmerman
Pages: 448 - 458
Patents
1 - 4 of 4
Linked dataset
1 - 1 of 1